Proactive Investors - Run By Investors For Investors

Imugene granted Canadian patent for proprietary cancer vaccine

Immunotherapies are predicted to generate sales of US$36 billion by 2025.
Imugene granted Canadian patent for proprietary cancer vaccine
Immuno-oncology is a relatively new but highly promising field

Imugene (ASX:IMU) has achieved a major milestone by securing a patent for its proprietary cancer vaccine, HER-Vaxx, from the Canadian Patent Office.

The company’s shares were last trading 13% higher intra-day, at A$0.017.

HER-Vaxx is a next generation cancer immunotherapy using B cell peptides, which harness the body’s ability to develop antibodies against the disease.

Immuno-oncology is a relatively new but highly promising field that uses the method of activating a patient's immune system against tumour growth.

Imugene is currently enrolling gastric cancer patients at eight key cancer hospital sites in Asia, including Hong Kong, Thailand and Taiwan.

HER-Vaxx works by targeting the same receptor (and additional receptors) as Herceptin and Perjeta, two of the leading antibody drugs on market, with annual sales of US$8.2 billion.

Current immunotherapies are predicted to generate sales of US$36 billion by 2025 but costs remain prohibitive for patients.

The mechanism of action for HER-Vaxx may help generate improved efficacy over existing treatments and at a lower cost.

Gastric cancer is a leading cause of cancer death worldwide, representing 10.1% of male cases, with the incidence of gastric cancer substantially higher in Asia.

Imugene had raised circa A$3 million as part of an option plan which expired on 31 March 2017, at a price of A$0.015 per share.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
salmon
January 31 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use